The pharmacokinetics of ciprofloxacin was studied in 12 volunteers during a 5-day course of 500 mg of ciprofloxacin given orally twice a day. The effects on the microflora of saliva and feces were also examined. Serum and urine samples were assayed for ciprofloxacin microbiologically, and the salivary and fecal microflora were examined quantitatively after processing onto a series of selective media. Fecal samples were also investigated for the presence of Clostridium difficile and its cytotoxin. The MICs for new colonizing bacteria were examined in the salivary and fecal samples. There was no accumulation during the course of 5 days with peak serum concentrations identical (2.8 and 2.3 mg/liter) after the first and final doses, and the areas under the serum curves were similar (9.6 mg/liter). The serum half-life was 2.5 h on both days. The changes in the salivary flora were minor and affected only the neisseriae. In the fecal flora, the numbers of enterobacteria and enterococci decreased markedly, whereas the changes in anaerobic flora (anaerobic cocci, fusobacteria, and bacteroids) were not so pronounced. However, 14 days after the drug was discontinued, the salivary and fecal flora were normalized in all respects. No new colonization of ciprofloxacin-resistant bacteria for which MICs were above 1.0 mg/liter was observed. C. difficile or its cytotoxin was not detected.
Ciprofloxacin, a new antibacterial agent belonging to the series of 4-quinolone carboxylic acids, is chemically related to the less antibacterially active nalidixic acid, norfloxacin, and ofloxacin (6, 11, 15) . Ciprofloxacin is highly active, with MICs mostly below 0.25 mg/liter for gram-negative aerobic rods (e.g., enterobacteria, including Serratia spp. and Enterobacter spp., and Haemophilus spp.) and oxidative rods (including Pseudomonas aeruginosa) and below 2 mg/liter for most gram-positive aerobic cocci. The substance is generally less active against anaerobic bacteria (11) , and the MIC for Clostridium difficile is between 4 and 8 mg/liter (1).
The present investigation was carried out to study the pharmacokinetics of ciprofloxacin in healthy volunteers, both men and women, during repeated dosing for 5 days and to assess the effects on the oropharyngeal and colonic microflora.
MATERIALS AND METHODS
Volunteers. Participating in the study were 12 healthy volunteers, six women and six men. They had a mean weight of 68.0 + (standard deviation) 10.6 kg (range, 54 to 85 kg) and were 26.0 + 2.6 (range, 21 Control (Statens Legemiddelkontroll), which are the governmental registration agencies approving new drugs.
Ciprofloxacin administration. Doses of 500-mg ciprofloxacin tablets (supplied by Bayer AG, Wuppertal, Federal Republic of Germany) were given with 100 ml of water every 12 h for 5 days. Tolerance was evaluated by questioning, physical examination, and clinical chemistry before the study and on days 3, 5, and 7 to 10 after drug administration.
Sampling procedures for assay of ciprofloxacin. Concentrations of ciprofloxacin were determined after the morning dose on days 1 selection or after operator-assisted choice of model and input of proper start parameters. The best-curve fits after oral doses were mostly achieved by the one-compartment open model with first-order absorption and elimination or, in two instances, after the final dose by the corresponding two-compartment model.
Statistics. Statistical significances between differences were assessed by the Wilcoxon nonparametric signed-rank test. A P value of <0.05 was considered significant. Results are expressed as means + standard deviations.
Sampling procedures for microbiological studies. Saliva samples were collected by spitting into sterile plastic tubes (5 ml) immediately before dosing on days 1, 3, and 5 of treatment and 2 and 14 days after cessation of treatment. Stool specimens were collected in sterile plastic containers on the same days. All specimens were immediately frozen and stored at -70°C until they were assayed.
Processing of specimens for microbiological studies. The saliva samples were suspended in prereduced peptone-yeast extract medium, diluted, inoculated onto selective media, and processed as described by Heimdahl and Nord (5) . The aerobic agar plates were incubated for 24 h at 37°C, and the anaerobic plates were incubated for 48 h at 37°C in anaerobic jars (GasPak; BBL Microbiology Systems, Cockeysville, Md.).
A 1-g sample of stool was homogenized in 9 ml of peptone-yeast extract medium. Tenfold serial dilutions were made to a dilution of 10-8. The samples were inoculated and processed as described by Heimdahl and Nord (5) . After incubation, total colony counts were determined from the aerobic and anaerobic blood agar plates. Different colony types were counted, isolated in pure culture, and identified, as were the different colonies appearing on the selective media.
All fecal samples were assayed for the presence of C. difficile and its cytotoxin by the method described by Aronsson et al. (1) .
Antibiotic susceptibility tests. The MICs of ciprofloxacin for the new colonizing bacteria were determined by using the agar dilution method (5) . RESULTS Concentrations of ciprofloxacin in serum and urine. The mean serum curves are shown in Fig. 1 . The concentrations on days 1 and 5 were completely overlapping. This is reflected by a mean area under the curve from 0 h to infinity of 9.6 mg/h per liter on both days (Table 1 ). The mean peak serum concentrations were 2.8 + 1.3 mg/liter after a period of 1.5 ± 0.35 h on day 1 and 2.3 ± 1.1 mg/liter after 1.5 ± 0.51 h on day 5. The areas under the curve were the same on days 1 and 5, and there was no significant difference between the sexes. The total amount of the dose excreted in urine during 12 h was 27.8 ± 10.5% after the first dose and 42.5 ± 17.6% after the final dose. Tolerance. Seven subjects experienced no untoward reaction and had no complaints of any kind during the 5-day period of ciprofloxacin administration or during the week after dosing. Two complained of initial headache, two had nausea, and one subject developed heartburn on day 5 of therapy. All symptoms were mild and resolved without specific measures. No change was noticed in serum or urine chemistry, and no crystals were observed in urine by microscopy.
Pharmacokinetics. The apparent lag before absorption was 0.53 h after the first dose and 0.2 h after the final dose ( Table  1 ). The serum half-life was 2.5 h on both days. Although the absolute mean serum half-life was shorter for the women, there was no significant difference between the sexes. The rate of absorption was quick, with a half-life of 0.22 h after the first dose.
6~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~...._..... Effect of ciprofloxacin on the salivary microflora. The effect of ciprofloxacin on the aerobic salivary flora is shown in Fig.  2 . The numbers of streptococci, staphylococci, and micrococci were not changed during the observation period, whereas in five patients harboring Neisseria species a decrease was observed during the administration period.
In the anaerobic salivary flora, no significant changes occurred in the numbers of microorganisms (Fig. 3) .
No new colonizing microorganisms resistant to ciprofloxacin (s1 mg/liter) were isolated from saliva during the investigation period.
Effect of ciprofloxacin on the fecal microflora. The aerobic fecal flora was partially suppressed (Fig. 4) . In all subjects the numbers of enterobacteria decreased significantly (P < 0.05). The enterococci were also markedly affected, whereas only minor changes were noticed in the numbers of staphylococci, streptococci, bacilli, and corynebacteria. The aerobic microflora had returned to normal in all subjects within 2 weeks after dosing was stopped. The anaerobic flora was also affected by ciprofloxacin (Fig. 5) . Thus, the numbers of anaerobic cocci, fusobacteria, and bacteroids decreased during the administration period, but 14 days after completion the anaerobic fecal flora reverted to normal in all subjects.
No new colonization with bacteria resistant to ciprofloxacin ('1 mg/liter) was observed. 
